论文部分内容阅读
近年来,辅酶Q_(10)(CoQ_(10))曾广泛用于心脏病人由于CoQ_(10)几乎不溶于水,口服片剂或细粉剂时,药物吸收不良。虽然曾以表面活性剂HCO-60增溶CoQ_(10),但增加肠内吸收量仍属有限。同时,由于合成的HCO-60影响胃肠发生病变,故含表面活性剂的制剂,其功效也是有限的乳剂系统也可促进胃肠道吸收亲脂性药物,并增加其生物利用度故制成乳剂型的CoQ_(10)。其吸收量可以增加然而目前乳剂系统因其不稳定性发生问题,现已很少应用新近Mizushi-
In recent years, coenzyme Q_ (10) (CoQ_ (10)) has been widely used in cardiac patients due to CoQ_ (10) almost insoluble in water, oral tablets or powder, poor drug absorption. Although CoQ_ (10) was solubilized with the surfactant HCO-60, the increase of intestinal absorption was still limited. At the same time, because the synthesis of HCO-60 affect the gastrointestinal lesions, so the formulation containing surfactant, its effectiveness is limited emulsion system can also promote the gastrointestinal tract to absorb lipophilic drugs, and increase its bioavailability so made of emulsion Type CoQ_ (10). Its absorption can be increased However, the current emulsion system due to its instability problems have now rarely applied the new Mizushi-